10-Q: NKGen Biotech Reports Q1 Net Income Amidst Delisting & Debt Defaults

NKGen Biotech reported a net income of $15.35 million for Q1 2025, primarily driven by non-cash gains, while facing significant liquidity challenges, debt defaults, and a delisting from Nasdaq.

Summary

• Reported net income of $15.35 million for the three months ended March 31, 2025, a significant improvement from a net loss of $5.38 million in the prior year period.
• The net income was primarily driven by a $21.58 million non-cash gain from the change in fair value of financial instruments.
• Operating loss improved to $4.67 million for Q1 2025, down from $7.62 million in Q1 2024.
• Research and development expenses decreased by 43% to $1.86 million, and general and administrative expenses decreased by 36% to $2.81 million, reflecting cost-cutting measures.
• Cash and cash equivalents stood at $6 thousand as of March 31, 2025, down from $106 thousand at December 31, 2024.
• Working capital deficit was approximately $41.5 million as of March 31, 2025.
• The company is in default under certain 2024 and 2025 Convertible Notes due to failure to remain current in SEC reporting obligations, leading to immediate repayment obligations and default interest rates (up to 24%).
• The company's securities were delisted from The Nasdaq Global Market on March 5, 2025, and subsequently moved to the OTC Pink Market, then the OTC Expert Market on July 17, 2025.
• Substantial doubt exists about the company's ability to continue as a going concern for the next 12 months due to expected operating losses and negative cash flows.
• Acquired a 65% majority equity stake in NKMAX, a Korean biotechnology company and former parent, on September 4, 2025, for approximately $16.9 million, primarily funded by AlpineBrook Capital GP 1 Limited and the CEO.
• Formalized $25.84 million in previously undocumented cash advances from AlpineBrook into a secured promissory note on January 5, 2026, bearing 12% interest and initially maturing March 2, 2026.

Sentiment

Score: 2

Explanation: The company is in severe financial distress, evidenced by critically low cash, a substantial working capital deficit, explicit going concern doubt, and defaults on debt. While there was a reported net income, it was driven by non-cash accounting adjustments, not operational profitability. The delisting from Nasdaq and repeated late SEC filings highlight significant operational and governance issues, overshadowing any clinical progress or cost reductions.

Positives

• Reported a net income of $15.35 million for Q1 2025, a significant turnaround from a net loss in the prior year, primarily due to non-cash gains on financial instruments.
• Operating loss decreased by 39% to $4.67 million in Q1 2025 compared to Q1 2024, indicating improved operational efficiency or reduced spending.
• Research and development expenses decreased by 43% to $1.86 million, and general and administrative expenses decreased by 36% to $2.81 million, contributing to reduced cash burn.
• Progress in clinical development with IND clearance for SNK01 in Parkinson's Disease (April 26, 2024) and SNK01 cleared to enter Phase 2 for moderate Alzheimer's disease (May 20, 2024).
• Phase I clinical trial data for SNK01 in Alzheimer's showed 30% clinical improvement and 60% stable ADCOMS scores, with evidence of crossing the blood-brain barrier.
• Phase I interim data for SNK02 in advanced solid tumors demonstrated Stable Disease in 100% of patients completing 8 cycles, indicating clinical activity.
• Successfully acquired a 65% majority equity stake in NKMAX, gaining control over global manufacturing infrastructure and intellectual property.
• Secured additional funding through various convertible notes, bridge loans, and stock purchase agreements, including significant capital contributions from AlpineBrook and the CEO.

Negatives

• The reported net income is primarily due to a non-cash gain from the change in fair value of financial instruments, not from operational profitability.
• The company has a limited operating history and has incurred significant operating losses since inception, with an accumulated deficit of $191.1 million as of March 31, 2025.
• Cash and cash equivalents are critically low at $6 thousand as of March 31, 2025, and the company has a working capital deficit of $41.5 million.
• Substantial doubt exists about the company's ability to continue as a going concern for the next 12 months, requiring immediate additional financing.
• The company is in default under certain 2024 and 2025 Convertible Notes due to late SEC filings, leading to immediate repayment obligations and increased default interest rates (up to 24%).
• Related Party Loans of $4.0 million are past due as of December 31, 2024, and terms are being renegotiated.
• The company's common stock and warrants were delisted from The Nasdaq Global Market on March 5, 2025, and now trade on the OTC Expert Market, significantly reducing liquidity and investor access.
• History of repeated late SEC filings, including this Form 10-Q, due to insufficient financial resources for timely valuations and accounting analyses, indicating material weaknesses in internal controls.
• The AlpineBrook Secured Note formalizes $25.54 million of previously undocumented cash advances, bears 12% interest, has a 20% cash premium on change of control, and includes a 24% default interest rate, imposing significant financial obligations and restrictive covenants.

Risks

• Ability to raise future financing and satisfy debt obligations when due or renegotiate terms.
• Reclassification or accounting adjustments related to the AlpineBrook secured promissory note.
• Ability to service operations, expenses, and other liquidity needs, and to continue as a going concern.
• Residual costs and expenses related to the Business Combination and other third-party payments.
• Changes in applicable laws or regulations.
• Ability to retain or recruit officers, key employees, or directors.
• Ability to successfully commercialize product candidates and obtain regulatory approvals.
• Uncertainty regarding the timing and results of clinical trial data and regulatory approval applications.
• History of operating losses and expectations of significant expenses and continuing losses for the foreseeable future.
• Ability to execute business strategy, develop and maintain brand/reputation, and partner with other companies.
• Ability to obtain and maintain intellectual property protection and not infringe on others' rights.
• Outcome of any legal proceedings.
• Unfavorable conditions in the industry, global economy, or global supply chain (e.g., financial/credit market fluctuations, international trade relations, pandemics, political turmoil, warfare, terrorist attacks).
• Risks related to the NKMAX acquisition, including failure of assets to perform, failure to realize expected profitability, environmental/regulatory compliance, foreign exchange fluctuations, and inability to retain key employees.
• Lack of expertise, personnel, and resources to successfully commercialize products if approved, and potential inability to establish effective marketing and sales capabilities.
• Current default under debt arrangements, with lenders potentially terminating forbearance and accelerating indebtedness, severely constraining liquidity and potentially leading to bankruptcy.
• Uncertainty regarding the finalization of previously undocumented AlpineBrook funding terms, which could be adverse to stockholders and creditors, including senior liens, restrictive covenants, and dilutive features.
• Inability to timely file periodic reports with the SEC due to insufficient funds, impacting future capital raising, public offerings, and investor perception.
• Ineffective Information Technology General Controls (ITGCs) leading to deficiencies in user access, program change management, and IT operations controls.

Future Outlook

The company expects to incur substantial operating losses for the next several years and will need to obtain additional near-term financing to continue research and development, initiate and complete clinical trials, and commercialize product candidates. Management has expressed substantial doubt about the company's ability to continue as a going concern. The company plans to fund losses through additional debt or equity financings from related parties, private equity, or other sources. They intend to advance clinical development of SNK01 in AD (Phase I/IIa in US/Canada) and complete Phase I for SNK02 in refractory solid tumors, with plans for a PD trial and strategic collaborations in oncology. The company is actively working to regain compliance with SEC reporting obligations and pursue relisting on a national securities exchange, potentially implementing a reverse stock split.

Management Comments

• "Our goal is to bring transformative Natural Killer (NK) cell therapies to patients with both neurodegenerative and oncological diseases and thereby realize the potential of our extensive NK cell expertise."
• "We do not currently have, and do not currently expect to have, sufficient funds to service our operations and our expenses and other liquidity needs and will require additional capital immediately."
• "There can be no assurance that we will be able to timely secure such additional funding on acceptable terms and conditions, or at all."
• "If we are unable to raise sufficient capital immediately, we will not have sufficient cash and liquidity to finance our business operations and make required payments and may be required to delay, limit, curtail or terminate our product development or may be forced to cease operations or file for bankruptcy protection."
• "The Company is actively working to regain compliance with its Exchange Act reporting obligations and has applied for listing on the OTCQB Market, with the application pending completion of required filings. Additionally, the Company intends to pursue relisting on a national securities exchange, such as Nasdaq or NYSE American, upon meeting applicable requirements."
• Dr. Yong Man Kim will continue as Chief Scientific Officer in a consulting capacity while serving as President of NKMAX, ensuring his involvement in scientific leadership and R&D strategy.

Industry Context

NKGen Biotech operates in the highly competitive and capital-intensive clinical-stage biotechnology sector, focusing on innovative autologous and allogeneic NK cell therapies for neurodegenerative diseases (Alzheimer's, Parkinson's) and cancer. The company's strategy to leverage its proprietary SNK platform and pursue strategic collaborations (e.g., HekaBio for Japan) aligns with industry trends seeking to accelerate development and commercialization in specialized therapeutic areas. However, the company's severe liquidity issues, debt defaults, and delisting from Nasdaq place it at a significant disadvantage compared to better-capitalized peers, potentially hindering its ability to compete effectively for talent, resources, and market share, despite promising early clinical data.

Comparison to Industry Standards

• NA

Management Changes

Corporate Governance

Legal Proceedings

• The company is not currently a party to or aware of any active legal proceedings that would have a material adverse effect on its financial position, results of operations, or cash flows. However, litigation can have an adverse impact due to defense and settlement costs and diversion of management resources.

Related Party Transactions

• Accounts payable and accrued expenses include $489 thousand owed to NKMAX as of March 31, 2025.
• Prepaid expenses and other current assets include $1.68 million associated with deposits paid to NKMAX to secure the Conditional Investment Agreement for the acquisition of NKMAX Co., Ltd.
• Related Party Loans with NKMAX for $4.0 million are past due as of December 31, 2024, and terms are being renegotiated.
• Senior Convertible Notes for $11.08 million are due to related parties (primarily NKMAX).
• Paul Y. Song, M.D. (CEO and Chairman) entered into a short-term bridge note with the company for $0.1 million on March 4, 2025, and personally guaranteed the EmpiriStat promissory note.
• AlpineBrook Capital GP 1 Limited, whose funding was personally guaranteed by Paul Y. Song, M.D. and James Graf, provided cash advances totaling $1.8 million during Q1 2025 (in addition to $3.1 million in 2024), which were formalized into a $25.84 million secured promissory note on January 5, 2026.
• Dr. Song also entered into a stock purchase agreement on May 5, 2025, to purchase 20,849,725 shares of common stock for $2.7 million and received a warrant for 41,699,449 shares.
• An existing investor (related party) entered into a stock purchase agreement on May 14, 2025, to purchase 19,669,552 shares for $2.5 million and received a warrant for 39,339,103 shares.

Stakeholder Impact

• **Shareholders**: Significant dilution from numerous equity issuances and warrant conversions. Risk of total loss of investment due to going concern doubt and potential bankruptcy. Reduced liquidity and trading access due to delisting to OTC Expert Market. Potential for further dilution from future capital raises and the AlpineBrook Secured Note's MFN provision and change of control premium.
• **Creditors**: Company is in default on certain convertible notes, leading to immediate repayment obligations and higher default interest rates. Related Party Loans are past due. The AlpineBrook Secured Note grants a security interest in substantially all U.S. personal property and Korean NKMAX shares, potentially impacting other creditors' recovery in a default scenario.
• **Employees**: Potential for reductions in spending, suspension or curtailment of programs, or cessation of operations if additional funding is not secured, impacting job security. Stock-based compensation may be affected by low share price and delisting.
• **Customers/Partners**: Clinical trial progress offers potential future benefits, but financial instability and operational challenges could impact the company's ability to deliver on collaborations or commercialize products.
• **Suppliers**: Risk of extended payment terms or non-payment if liquidity issues persist, potentially straining relationships.

Next Steps

• Obtain additional near-term financing through debt or equity to fund operations, research, and clinical trials.
• Continue to advance the clinical development of SNK01 and enroll patients in the Phase I/IIa trial in the United States and Canada for Alzheimer's Disease.
• Complete the Phase I trial with SNK02 in refractory solid tumors.
• Conduct a trial in Parkinson's Disease and evaluate expansion into other neurodegenerative diseases.
• Accelerate development in oncology through strategic collaborations.
• Continue investment in manufacturing technology.
• Regain compliance with SEC reporting obligations and complete required filings for OTCQB Market listing.
• Pursue relisting on a national securities exchange (Nasdaq or NYSE American) upon meeting applicable requirements, potentially implementing a reverse stock split.
• Renegotiate terms for the past-due Related Party Loans.
• Finalize terms, structure, and documentation for the AlpineBrook funding, which was formalized as a secured promissory note.

Key Dates

Recommendation

The company faces severe financial distress, explicitly stating 'substantial doubt' about its ability to continue as a going concern. Its cash position is critically low, and it operates with a significant working capital deficit. The reported net income is misleading, being driven by non-cash accounting gains rather than operational profitability. Furthermore, the company is in default on multiple debt obligations, has a history of late SEC filings, and has been delisted from Nasdaq to the OTC Expert Market, severely impairing liquidity and investor confidence. While there is clinical progress and strategic acquisitions, the overwhelming financial and operational risks, coupled with potential for significant further dilution and the possibility of bankruptcy, make the stock a strong sell for any seasoned investor or institution.

Keywords

Biotechnology, Cell Therapy, NK Cell Therapy, SNK Platform, Alzheimer's Disease, Parkinson's Disease, Solid Tumors, Clinical Trials, SEC Filing, 10-Q, Going Concern, Debt Default, Delisting, Capital Raise, Warrants, Convertible Notes, NKMAX Acquisition, Financial Instruments, Liquidity, Corporate Governance